As per the report, the size of the global dendritic cell cancer vaccines market is forecasted to grow at a robust CAGR of 12.09% from 2023 to 2028.
Human tumors express several protein antigens that can be recognized by T cells; thus, it provides potential targets for cancer therapy. Dendritic cells are rare leukocytes that are uniquely potent in their ability to present antigens to the T cells; according to WHO, around 9.6 million people died in 2018. Also, about 300000 cases were detected in children aged 0 – 19 years. The isolated dendritic cells are loaded with tumor antigen ex vivo. They are administrated as a cellular vaccine and have been found to induce protective and therapeutic anti-tumor immunity during the experiment. Cancer vaccine is a market that researchers and patients have highly valued since it leads to a high survival rate and fewer possibilities of cancer recurrence; consequently, the inclusion of dendritic cells into cancer vaccine is predicted to enhance further vaccines functioning mechanism against different sorts of cancers.
Growing incidence of cancer across the world and raising funds for the development of new vaccine-related diseases from public and private organizations are majorly promoting the global dendritic cell cancer vaccines market. The allogeneic dendritic cells are used to create a vaccine for COVID-19. Ongoing research on the development of vaccines to cure tumor cells is escalating the demand in the market. Increasing disposable income in developed and developing countries are levelling up the growth rate of the market.
Current and new technological platforms to develop novel cancer vaccine variations are propelling the global dendritic cell cancer vaccine market growth.
Many studies have shown dendritic cells have the potential ability in combinational therapies to restrict cancer growth. The growth of the dendritic cell cancer vaccine market is expected to be fuelled by increased investments in research & development and excellent clinical trial findings. Owing to a lucrative development in the pipeline, the global dendritic cell vaccine market has managed to catch the attention of numerous important investors and stakeholders. Furthermore, the Partnerships in the regional market that have recently taken place, such as clinical trial collaborations and research collaborations, have aided the global dendritic cell cancer vaccines market expansion.
The rising adoption of personalized medicine, growing support from the governments for the R&D of dendritic cell cancer vaccines and increasing awareness among healthcare providers and patients regarding the potential benefits of cancer immunotherapy boost the growth rate of the segment. In addition, the favorable regulatory environment for dendritic cell cancer vaccines, the growing number of investments by the market participants for the development of new and advanced dendritic cell cancer vaccines, rising healthcare expenditure and the growing aging population worldwide drive the market growth. Furthermore, rising awareness about the benefits of immunotherapy including dendritic cell cancer vaccines and the growing adoption of combination therapies fuel the market’s growth rate.
The growth of the global dendritic cell cancer vaccine market is progressively diminishing due to a lack of understanding of using vaccinations in various forms. The government's strict restrictions and restrictions are also limiting the market for dendritic cell vaccines. The market's development pace is also being slowed by a scarcity of experienced personnel at research institutes.
Impact of COVID-19 on the global dendritic cell cancer vaccines market:
The cancer vaccine market substantially affected growth due to the abrupt advent of the worldwide COVID-19 pandemic. Around 210 nations have been affected by COVID-19. COVID-19 has had a limited impact on cancer vaccine production and distribution enterprises, owing to shutdowns in several COVID-19-affected countries and a rise in the number of healthcare personnel becoming ill due to the pandemic, resulting in a shortage. As the number of COVID-19 cases increased globally, healthcare systems turned their priority to containing the illness, delaying the prevention, diagnosis, and treatment of other chronic diseases such as cancer. As a result, the cancer vaccine market is now predicted to have a negative impact. However, due to the removal of limitations and the resumption of R&D activities and clinical trials for cancer vaccines, the market is likely to gain traction in the future years.
Market Size Available
2022 to 2028
2023 to 2028
By Product Type, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This market research report on the global dendritic cell cancer vaccines market has been segmented based on the product type, end-user, and region.
Dendritic Cell Cancer Vaccines Market - By Product Type:
Based on product type, the Sipuleucel-T (Provenge) segment accounted for the largest market share of the dendritic cell cancer vaccines market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The drug sipuleucel-T has been authorized for use in males with metastatic prostate cancer. As it grows in popularity During the projection period, Sipuleucel-T is expected to increase its market share. Melanoma, prostate cancer, and other cancers are treated with it. The FDA gave it its approval nearly seven years ago. As it is, the market leader continues to its growth during the forecast period.
During the forecast period the creavax segment is anticipated to grow at a healthy CAGR during the forecast period. The segmental growth is driven by the rising adoption of personalized immunotherapy treatments for cancer.
Dendritic Cell Cancer Vaccines Market - By End User:
Based on end-user, the adult segment had the largest share of the worldwide market in 2022 and is expected to grow at a promising CAGR during the forecast period. The segmental growth is majorly driven by the growing prevalence of cancer among adults, rising demand for immunotherapy-based treatments and the development of new vaccines, such as those targeting solid tumors.
Dendritic Cell Cancer Vaccines Market - By Region:
The Middle East and Africa
Regionally, the North American dendritic cell cancer vaccines market had the largest share of the worldwide market in 2022 and is estimated to play a leading role in the worldwide market throughout the forecast period. The growth of the North American market is majorly driven by the high incidence of cancer, increasing healthcare expenditure, and the presence of key players in the region. The rising demand for immunotherapy-based treatments is another major factor fuelling the regional market growth. The U.S. accounted for a notable share of the North American market in 2022 and is estimated to grow at a noteworthy CAGR during the forecast period owing to the growing cancer patient population and the presence of favourable reimbursement policies.
Europe dendritic cell cancer vaccines market was the second biggest regional market worldwide market in 2022 and is expected to grow at a notable CAGR during the forecast period. Factors such as increasing incidence of cancer, the presence of key players, and favorable reimbursement policies drive the regional market growth. The UK occupied the major share of the worldwide market in 2022. Germany is estimated to showcase a healthy CAGR during the forecast period.
APAC dendritic cell cancer vaccines market is expected to grow at the highest CAGR in the worldwide market during the forecast period. The rising incidence of cancer, increasing demand for innovative treatments, the presence of a large patient population, a large number of clinical trials for dendritic cell cancer vaccines majorly propel the APAC market growth. Japan and China accounted for the major share of the APAC market in 2022.
Latin America dendritic cell cancer vaccines market and MEA dendritic cell cancer vaccines market continue to lag and will remain the least attractive markets all through the forecast period.
KEY MARKET PARTICIPANTS:
Some of the promising companies operating in the global dendritic cell cancer vaccines market profiled in the report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, and Merck & Co.
RECENT MARKET DEVELOPMENTS:
On May 5, 2020, Lineage Cell Therapeutics Inc. developed a vaccine for COVID–19 with the help of allogeneic dendritic cells.
On June 2, 2020, NW Biotherapeutics Inc. developed DCVax personalized immune therapy for solid tumors (glioblastoma brain cancer). It has entered the III phase of the clinical trial.
On May 18, 2020, OSE Immunotherapeutic announced that new preclinical data identified a novel myeloid immune checkpoint target for cancer immunotherapy.
3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, and Merck & Co are some of the key market players in the dendritic cell cancer vaccines market.
The North American dendritic cell cancer vaccines market is expected to grow significantly and hold the largest revenue share during the forecast period.
The global dendritic cell cancer vaccines market is expected to grow at a CAGR of 12.09% during the forecast period.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]